Aurora Spine has received multi-site selection approval from Institutional Review Board (IRB) for its new trial of the DEXA-C Cervical Interbody System.

The multi-centre trial has selected seven centres and three have been submitted for approval. Subject enrolment for the trial is expected to commence on securing approval.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The trial will initially include results obtained from 40 single-level and 40 multiple-level patients.

The primary outcomes of interest for this trial will be fusion evaluation with patient follow-up visits at three, six, 12 and 24 months after surgery.

The data collection will feature fusion assessment from Static and Dynamic X-Ray (AP/LAT/Flex/Ex) using the bridging bone inside or outside of graft; no lucencies at the graft-vertebral body junction; and motion < 1mm criteria.

Subsidence and alignment assessments will be included as the secondary outcome measures in the trial.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

At follow-up visits, the trial will collect patient-reported outcomes (NDI and VAS) and evaluate them against the baseline.

Aurora Spine president, CEO, and co-founder Trent Northcutt said: “We’ll be sure to make periodic updates of this study, with the next steps being the enrollment of patients at these locations.

“The data from this study will be very important to doctors’ thinking about using the DEXA-C series of implants and will help build out our DEXA franchise.”

Indicated for procedures related to anterior cervical interbody fusion, the DEXA-C system is the first in a series of implants based on the patented DEXA technology platform of Aurora.

The system can be used on patients requiring anterior cervical discectomy and fusion surgery and implants an interbody spacer(s) into the cervical intervertebral body space(s) for stabilising the level(s).

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact